Longeveron’s laromestrocel shows fewer major adverse cardiac events in Phase 2b trial

• Longeveron reported updated ELPIS II Phase 2b results showing laromestrocel significantly reduced major adverse cardiac events in infants with hypoplastic left heart syndrome.
• The trial previously failed its primary goal of improving right ventricular pumping function at 12 months.
• Laromestrocel showed favorable safety through 12 months, with no treatment-related serious adverse events identified.
• The company plans to request an FDA meeting to review results and determine potential next steps for the development program.
• Results will be presented at the American Heart Association’s Scientific Sessions in Chicago on November 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260915PRIMZONEFULLFEED9852871) on October 26, 2026, and is solely responsible for the information contained therein.